Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical tr…
Biotechnology
US, Gaithersburg [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Arcellx, Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2022 | -1.7900 | -5.236 | 0 | 2 | -63 | -251 | -65 | 1 | -66 | 1 | 18 | 1 |
| 2023 | -4.2200 | -2.472 | 0 | 67 | -186 | -122 | -186 | 43 | -193 | 43 | 41 | 61 |
| 2024 | -1.4700 | -1.403 | 110 | 131 | -70 | -67 | -87 | 84 | -89 | 83 | 64 | 120 |
| 2025 | - | -2.301 | - | 114 | - | -134 | - | 73 | - | 73 | - | 105 |
| 2026 | - | -2.561 | - | 147 | - | 2.F4X/td> | - | 2.F41/td> | - | 2.F41 | - | 2.F41 |
| 2027 | - | -2.026 | - | 187 | - | 1.F5X/td> | - | 1.F51/td> | - | 1.F51 | - | 1.F51 |
| 2028 | - | -0.802 | - | 325 | - | 0.F6X/td> | - | 0.F61/td> | - | 0.F61 | - | 0.F61 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
Overweight
Prev. Grade
n/a
Nov. 21, 2024
Overweight
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-13.084% $11.49 · MISS
Nov. 6, 2024Price Then
$87.12
Price Target
$99.31
Price Now
$87.82